Phase 4 Studies on Phosphodiesterase 5 Inhibitors

JAMA Ophthalmol. 2022 May 1;140(5):484-485. doi: 10.1001/jamaophthalmol.2022.0664.
No abstract available

Publication types

  • Clinical Trial, Phase IV
  • Comment

MeSH terms

  • Humans
  • Phosphodiesterase 5 Inhibitors* / adverse effects

Substances

  • Phosphodiesterase 5 Inhibitors